Indian firm Biocon halts China plans for generic Ozempic/Wegovy due to local competition, as Chinese firms develop 15+ biosimilars before 2026 patent expiry.

• Biocon skips the China market for Novo Nordisk diabetes/weight loss drugs amid strong local competition and existing biosimilar projects.
• Chinese drugmakers rush to develop 15+ generics/biosimilars for Ozempic/Wegovy as the semaglutide patent expires in 2026.
• China’s obesity crisis grows, with 540 million overweight and 150 million obese adults projected by 2030, boosting demand for treatments.